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Immunization with cancer cells is of great demand in anti-cancer therapy. However, current cellular 
vaccines are inefficient and there are questions regarding their overall safety. We report a simple and 
straightforward approach for improving of cellular cancer vaccines. Through treatment of cancer cell 
cultures with purified protease, it is possible to make preparations of cell-surface antigens that are free of 
intracellular content and contain two orders-of-magnitude less protein than the whole lysate of an 
equivalent number of cancer cells. Despite this difference in total protein content, protease-generated 
preparations stimulate anti-cancer responses from immune cells better those stimulated with cancer cells 
themselves. The composition of collected cell-surface antigens, prior to vaccination, can be directly 
compared with antigenic profile of target cancer cells by the proteomic footprinting. Any contaminates 
(cell parasites, viruses, toxins, prions, etc.) are easily separated from antigens by means of ultrafiltration. 
Thus, current cellular vaccines may be improved by replacing whole cancer cells with their isolated cell-




The efficacy of whole-cell cancer vaccines 
have been investigated for more than 20 years in 
both preclinical models and in clinical trials in 
humans.1-3 There are clear advantages of whole-cell 
vaccination over types of immunotherapy that 
target specific antigens. Multiple and unknown 
antigens may be targeted by both the innate and 
adaptive immune system. However, with few 
notable exceptions, immunization with whole-cell 
vaccines has not resulted in significant long-term 
therapeutic benefits.4-5 One possible explanation is 
that as only a small portion of cancer cell 
constituents are useful ‘targets’ for specific 
immune responses.6 Figure 1 shows the 
approximate ratio of intracellular content to 
extracellular content. Intracellular content is 
sequestered within cells and therefore, less useful 
as antigens for vaccination, as only exposed, 
extracellular domains are accessible for humoral 
and cytotoxic immunity. Additionally, only a 
minority of cellular molecules can be considered 
useful targets for immune therapy because the 
vast majority of cellular constituents are not 
specific to cancer cells, including products of 
normal ‘housekeeping’ genes, carbohydrates, 
nucleic acids, and other contents that are 
ubiquitous among all mammalian cells. Not 
surprisingly, the immune responses in cancer 
patients are often insufficient to result in cancer 
rejection following cancer vaccine immunization. 
Therefore, vast improvements to cellular cancer 





Figure 1. Ratio of surface targets which are accessible for 




Approach to improving vaccines 
 
One possible and attractive approach 
for improving cellular cancer vaccines is to 
isolate essential targets of cancer cells and use 
them in vaccines instead of the whole cells. The 
meaningful targets for immune responses are 
mainly domains of surface-expressed proteins 
and glycoproteins that are accessible to 
antibodies and cytotoxic immune cells. These 
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therefore, potentially can be isolated by 
proteolytic cleavage. The antigen profile obtained 
by proteolytic cleavage contains a comprehensive 
set of native antigens that can be used to direct 
immuno-therapeutics while minimizing the portion 
of ubiquitous molecules that are not useful targets. 
This approach to antigen isolation could potentially 
improve the efficiency with which cancer vaccines 
can be developed.  
 
 
The ‘bottleneck’ in the approach 
 
Improvement in developing cancer 
vaccines using this approach seems evident. 
Despite the fact that isolation of cell-surface 
molecules with proteases was described many 
years ago,7-12 as well as use of cancer cells for 
vaccination, limitations in the applicability of such 
an approach were overcome only recently. Mainly, 
they concern protease impurity and cellular 





Trypsin (activity ~200 U/mg), at working 
concentration about 300 µg/ml, is widely used to 
cleave cell surface proteins.7,13 Using 1 ml of such a 
trypsin solution can treat up to 5 × 106 cancer cells, 
which yield only 10-20 µg of cell-surface molecules. 
Thus, the quantity of protease is significantly 
greater than the quantity of collected cell-surface 
protein. Notably, the trypsin preparation contains 
numerous admixtures, including other proteases, 
differently degraded forms of trypsin, and 
autolysis products. Relatively more purified 
preparations of trypsin can be made, but they also 
generate numerous autolysis peptides during their 
actions.14 Separating the trypsin admixtures from 
the population of collected cell-surface antigens is a 
complex task. These multistage and relatively 
complex approaches, which have been described 
in numerous sources,7,10,15-23 only are used for 
separation and characterization of the limited 
number of separate antigens and are not 
applicable directly for vaccine production.  
It is clear that only highly-purified trypsin 
should be used to produce preparation of cell-
surface antigens directly from cancer cells. Trypsin 
concentrations of ~25 µg/ml, which correspond to 
trypsin activity > 3000 U/mg, can be used to 
generate cell-surface antigens with less protease 
impurity. It has recently been demonstrated that 
live cell treated with proteomics grade trypsin 
(5000 U/mg) resulted in solution of cell specific 
peptides.24 Therefore, using trypsin of higher 
purity, e.g. modern trypsin preparations with 
activity up to 20000 U/mg, generates 
preparations of cell-surface antigens that contain 
negligible amounts of trypsin admixtures.  
 
 
Cellular damage during manipulation 
 
Animal cells are sensitive to fluid 
shearing in serum-free medium.25-28 Therefore, 
any manipulation with cells in serum-free 
medium, which is required to obtain cleared cell 
surface antigens, leads to cell-membrane 
damage that releases intracellular content. 
Moreover, the protease itself may cause cell 
death during long treatments. Shown in Figure 1, 
the quantity of cell surface antigens from 100 
cancer cells is comparable to the quantity of 
intracellular molecules from just a single cell. 
Therefore, a critical aspect in preparing cell-
surface antigens is to minimize the destruction 
of cells by fluid shearing during manipulation. 
Figure 2 shows that optimizing protocol 
conditions lead to observed death rate of < 0.1% 
of adenocarcinoma cells. Thus, we conclude that 
treating live cells with proteases allows 
collection of cell-surface antigens and prevents 





Figure 2. In situ trypan blue staining of human breast 
adenocarcinoma cells (MCF-7) after cell treatment with 
trypsin (0.2 µg/mL, activity 15000 U/mg) solution for 25 min. 
Dye strained dead cells in blue color.  
 
 
For more shear-sensitive cell cultures, 
application of cyto-protectants significantly 
decreases the cell death rate during 
manipulations,25 and may results in a cell antigen 
preparation of even greater purity. Figure 3 
summarizes the influence both described 
conditions (protease impurity and cell death 
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Figure 3. Effects of trypsin impurity and cell death rate on cell-
surface antigen preparations. The light-green region 
corresponds to conditions when cell-surface antigen 
preparations are adequate for use.  
 
 
Proof-of-concept in vitro 
 
To confirm that proteolytically-cleaved 
cell-surface antigens are sufficient for vaccination, 
their immunogenic properties were compared to 
that of whole cells. In a cytotoxicity assay, as an in 
vitro model of human anti-tumor therapies, human 
cytotoxic T-lymphocytes (CTLs) were incubated 
with target adenocarcinoma cells (MCF-7). CTLs 
were stimulated with dendritic cells (DCs) loaded 
with cell-surface antigens. DCs loaded with lysate 
of whole cancer cells were used for comparison. 
Generation of DCs29 and cytotoxicyty assay were 
performed according to widely accepted 
protocols. 
Visual inspection of target cancer cells in 
the cytotoxicity assay (Figures 4) revealed that 
that DCs loaded with cell-surface antigens induce 
cytotoxicity as effectively as DCs loaded with 
lysate. More precise calculation of dead target cells 
revealed that cell-surface antigens were ~20-30% 
more effective than lysate. Simultaneously, the 
whole-cell lysate contained 270 µg/mL protein, 
while the used solution of cell surface antigens 
contained 2 µg/mL.  
Despite the solution of cell-surface 
antigens contained 2 orders-of-magnitude less 
protein than the lysate, it had the same ability to 
induce cytotoxic activity in CTLs. This is due to the 
necessary antigens being present in the solution of 
cell-surface antigens that is free of intracellular 
substances. This is a proof-of-concept, that the 
treatment of live cancer cells with proteases leads 
to the release of antigenic targets from cells that 
are sufficient to induce anti-cancer immune 
response in vitro. This leads to the possibility of 
using these preparations instead of cells as 






Figure 4. Lysis of human breast adenocarcinoma cells in 
cytotoxicity assay. 
Target adenocarcinoma cells (MCF-7) were incubated with 
effector cytotoxic T-lymphocytes (CTLs) at ratio 4:1. On the 
3rd day, target cells were carefully washed and photographed 
on an inverted phase contrast microscope. (a) Control cells 
grown alone. (b) Cancer cells incubated with CTLs that had 
been stimulated with dendritic cells loaded with lysate of 
cancer cells. (c) Cancer cells incubated with CTLs that had 




Future prospect of vaccines certification 
 
Cultivated cell studies have indicated 
that cross-contamination between cell lines is 
widely prevalent and continues to be a major 
problem.30-34 From the existing estimates, up to 
36% of cell lines already appear to have a 
different origin than their initial cell lines. 34-35 
Of the known authentication methods, 
short tandem repeat profiling (DNA 
fingerprinting)35 is widely used and powerful 
method that provides an international reference 
standard for authentication of human cell lines.36 
However, in the case of cellular cancer vaccines, 
distinguishing surface antigens of target cancer 
cells and surface antigens of vaccines' cells is 
required. 
Cultivated mammalian cells have a finite 
mitotic lifespan,37-39 which is followed by cellular 
degeneration and modifications in cell-surface 
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been passaged extensively in vitro, and 
considerable variation and genomic instability have 
been observed in long-term cultures.42-43 
Moreover, even cell lines that have been in culture 
for a relatively brief period of time, have displayed 
marked differences even from cultures derived 
from the same specimen.44 This heterogeneity is 
pronounced at the genomic level and reflected in 
antigen expression. It might represent responses 
to selective pressures in vitro,44 which lead to 
divergence of the cellular phenotypes over time.  
In light of this, cultivated tumor cells 
intended for therapy must be analyzed for changes 
in their profile of surface antigens by comparing 
them with antigen profile of reference cancer cells. 
Current cancer vaccines which are already in 
clinical trials45 have not passed such tests, partially, 
because there is no routine method of analysis. 
Intracellular content in these vaccines is prevalent 
and makes the composition of cell-surface antigens 
difficult to identify.  
Cell surface antigens produced by our 
method are largely free of intracellular contents 
and suitable for direct mass spectrometric analysis. 
This is related to cell proteomic footprinting, a 
simple approach for authentication and 
characterization of cells with high speed and low 
sample cost ($15 per sample).24 Through the direct 
comparison, compositions of cell-surface antigens 
with the proteomic footprints of the reference 
cells can be easily certificated for the proper use. 
 
Safety of improved vaccines 
 
A potential limitation with current cell-
based vaccines is the difficulty associated with 
purifying cells from possible dangerous 
contaminants such as cell parasites, viruses, 
toxins and prions. Improving this aspect is 
essential for cell-based vaccines.46-47 
Proteolytically-cleaved cell-surface antigens are 
peptides and glycopeptides. Therefore, simple 
ultrafiltration aimed to remove macromolecules 





Further characterization of 
proteolytically-cleaved cell surface antigens, 
such as the choice of adjuvant and schedule, is 
required for vaccine development. However, the 
diversity of native tumor-associated antigens, 
low levels of undesirable antigens, and purity 
regarding dangerous intracellular agents, and 
possibility for certification demonstrates the 
potential for using cell-surface antigens as anti-
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